TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00306267
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01528345
Drug: Dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Study: NCT01528345
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
Study: NCT01528345
Drug: Dovitinib Placebo
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
Study: NCT00236600
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03618043
Drug: SH-1028
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
Study: NCT02601976
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
Study: NCT02601976
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01182883
Drug: IMC-A12
Normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01182883
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02423148
Drug: Indocyanine green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04012476
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
Study: NCT00744757
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
Study: NCT02524054
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Study: NCT01712659
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
Study: NCT01712659
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
Study: NCT01712659
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
Study: NCT01712659
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
Study: NCT01390077
Drug: Nitisinone
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
Study: NCT02534506
Drug: Urelumab
Normalized name: Urelumab
DrugBank: Urelumab (DB12077)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534506
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02976571
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub cutaneous and/or Intraperitoneal Marcaine application
Study: NCT00006015
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/sq m IV infusion over 2 hours Days 1 \& 15 of each cycle
Study: NCT00866905
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
Study: NCT03398473
Drug: Epoetin Hospira SDV
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin Hospira Single Dose Vial
Study: NCT03398473
Drug: Epoetin Hospira MDV
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin Hospira Multi-Dose Vial
Study: NCT00185315
Drug: Ventavis (Iloprost, BAYQ6256)
Normalized name: Ventavis
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled iloprost
Study: NCT03026946
Drug: cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
Study: NCT00601159
Drug: gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
Study: NCT00948766
Drug: Rivastigmine 4.6 mg/24 h (5 cm^2)
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.
Study: NCT00948766
Drug: Rivastigmine 9.5 mg/24 h (10 cm^2)
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.
Study: NCT00948766
Drug: Rivastigmine 13.3 mg/24 h (15 cm^2)
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.
Study: NCT01757431
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00203801
Drug: Sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00203801
Drug: Artesunate plus sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00683423
Drug: BMS-741672
Normalized name: BMS-741672
DrugBank: BMS-741672 (DB19004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 100 mg, once daily, 3 weeks
Study: NCT03403569
Drug: Triptolide Wilfordii
Normalized name: Geranium wilfordii top extract
DrugBank: Triptolide (DB12025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
Study: NCT04085185
Drug: IBI110+ Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit.
Study: NCT04085185
Drug: IBI110+ Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit.
Study: NCT02806648
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib
Study: NCT01303679
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV, 80mg/m² at d1, d8, d15
Study: NCT01303679
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
Study: NCT01303679
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily 25 mg (1 pill) oral intake
Study: NCT01028781
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
Study: NCT00485862
Drug: Atomoxetine Hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00485862
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02979704
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
Study: NCT00160511
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03456466
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 ，iv
Study: NCT00652444
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
Study: NCT04326166
Drug: Evogliptin
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin
Study: NCT04326166
Drug: Metformin and Evogliptin
Normalized name: metformin and evogliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin and Evogliptin
Study: NCT03426605
Drug: Open Label LAM-003
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM-003
Study: NCT00229476
Drug: sertraline (Zoloft)
Normalized name: sertraline Oral Solution [Zoloft]
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00221026
Drug: Methoxsalen +ECP
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECP + Uvadex given at weeks 1-12 weeks.
Study: NCT00372424
Drug: Herceptin
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
Study: NCT00372424
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
Study: NCT00372424
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
Study: NCT00649974
Drug: Valacyclovir Hydrochloride Tablets 1000 mg
Normalized name: Valacyclovir Hydrochloride
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg, single dose fasting
Study: NCT03977012
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5\~20 mcg
Study: NCT00386139
Drug: Aliskiren/HCTZ
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00527592
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
Study: NCT00527592
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
Study: NCT00004583
Drug: Lopinavir/Ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04157010
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01219543
Drug: AZD1480 Daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Dose, Capsule, Daily Dosing
Study: NCT02200146
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
Study: NCT02200146
Drug: Hydroxychloroquine + Prednisone
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
Study: NCT00004583
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004583
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004583
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02806440
Drug: Low dose naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT02027025
Drug: SPARC1103 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once daily
Study: NCT02027025
Drug: SPARC1103 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT02078908
Drug: Sodium nitrite, 40 micrograms/kg/hour
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
Study: NCT00909064
Drug: Fondaparinux Sodium (Arixtra)
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
Study: NCT02078908
Drug: Sodium nitrite, 120 micrograms/kg/hour
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
Study: NCT02078908
Drug: Sodium nitrite, 240 micrograms/kg/hour
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
Study: NCT02700347
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02700347
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00537888
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous or oral 400 md/d
Study: NCT03775083
Drug: Currently approved medications
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
Study: NCT00003288
Drug: tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04467840
Drug: Opaganib
Normalized name: Opaganib
DrugBank: Opaganib (DB12764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
Study: NCT01119521
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
Study: NCT01542450
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
Study: NCT01894243
Drug: Olaparib tablet dosing
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
Study: NCT03688451
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrathecal administration over 3-5 minutes
Study: NCT01796548
Drug: Oxybutinin Extended-Release
Normalized name: oxybutynin Extended Release Oral Tablet
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
Study: NCT02713178
Drug: bupivacaine liposome injectable suspension
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
Study: NCT01239459
Drug: Teriflunomide HMR1726
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition
Study: NCT01239459
Drug: Cholestyramine
Normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55
Study: NCT00567034
Drug: naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg naltrexone, 1 tablet a day for 12 weeks.
Study: NCT01836068
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
Study: NCT00479674
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
Study: NCT00479674
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
Study: NCT00479674
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
Study: NCT00268229
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2/day
Study: NCT00268229
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 45 mg/m2/day